What is JenaValve?
Founded in 1995 and headquartered in Irvine, California, JenaValve is dedicated to advancing cardiac care through its proprietary native aortic valve leaflet technology. The company's offerings aim to provide less invasive and more effective treatment options for patients with aortic valve disease. JenaValve's commitment to innovation positions it as a key player in the competitive medical device landscape, focusing on improving patient outcomes and addressing unmet clinical needs within the cardiovascular field.
How much funding has JenaValve raised?
JenaValve has raised a total of $283.3M across 8 funding rounds:
Series A
$14M
Private Equity
$13.5M
Series B
$19M
Private Equity
$10M
Private Equity
$9.4M
Debt
$4.9M
Other Financing Round
$50M
Series C
$162.5M
Series A (2007): $14M with participation from Edmond de Rothschild Investment Partners and Atlas Venture
Private Equity (2010): $13.5M, investors not publicly disclosed
Series B (2010): $19M supported by VI Partners AG, Gimv, and Sunstone Capital
Private Equity (2016): $10M, investors not publicly disclosed
Private Equity (2017): $9.4M, investors not publicly disclosed
Debt (2018): $4.9M, investors not publicly disclosed
Other Financing Round (2020): $50M led by Bain Capital LP, Legend Capital Co. Ltd, Valiance Asset Management Limited, NeoMed Management, Gimv, RMM Solutions Inc, Andera Partners, and VI Partners AG
Series C (2022): $162.5M supported by Andera Partners, Valiance Advisors, Gimv, and Bain Capital Life Sciences
Key Investors in JenaValve
Valiance Asset Management Limited
Valiance Asset Management is a global investor focused on impactful technology businesses, aiming to provide life-changing opportunities and improve quality of life through strategic investments in emerging technology firms.
Gimv
Gimv is a European investment company specializing in mid-market businesses across key sectors like Healthcare and Life Sciences, fostering sustainable growth through long-term investment and collaboration with management teams.
VI Partners AG
V I Partners is a business advisory and wealth planning firm that specializes in accounting, compliance, business profit improvement, and wealth planning, focusing on understanding unique client needs and goals.
What's next for JenaValve?
With the recent infusion of $162.5M in a major strategic investment, JenaValve is poised for accelerated development and market expansion. This capital injection is expected to fuel further research and development, enhance manufacturing capabilities, and broaden the commercial reach of its advanced aortic valve solutions. The company's strategic focus will likely involve scaling operations to meet growing demand and solidifying its position as a leader in the medical device industry, particularly within the critical field of cardiac valve replacement.
See full JenaValve company page
